Alexander I. Tröster, Ph.D. Department of Neurology

Slides:



Advertisements
Similar presentations
APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Advertisements

Early Detection of Cognitive Disorders Robin J. Heinrichs, Ph.D., LP Neuropsychologist & Assistant Professor Director of Neuropsychology Laboratory.
Frontotemporal Dementia
Neuropathology and Cognitive Scores Workgroup The role of vascular and Alzheimer’s Disease pathology in differential cognitive impairment among older adults.
Parkinson’s Cognitive Problems versus Other Neurological Diseases 14 February 2015 Carole A. Mazurowski, PhD Health Psychology & Neuropsychology 6565 Americas.
Screening for Alzheimer’s disease Herman Buschke, MD Einstein Aging Study (NIA AG-03949) Department of Neurology Albert Einstein College of Medicine.
Brief Cognitive Assessment Tool (BCAT®) Training Program
Ontologies for the Study of Neurological Disease Mark Jensen ICBO 2012—Workshop on Mental Functioning July 22, Graz, Austria.
Tony WAEGEMANS, MD UCB Pharma, Belgium. TW/ll/ Washington/MCI 2 MCI as implemented in our study MCI is a very early stage of dementia with as main.
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
Mary Ganguli’s Slides March 13 th Meeting. Mild Cognitive Impairment A View from the Trenches.
Screening By building screening for symptoms of VCI into regular workflows or practice, health care providers are participating in Taking Action to address.
The New Brief Cognitive Assessment Tool (BCAT): The Role of Cognitive Assessment in Improving Health Outcomes Dr. William Mansbach October 25, 2011.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Dementia with Lewy Bodies
Mild Cognitive Impairment
ACT on Alzheimer’s Disease Curriculum Module VI: Screening.
ACT on Alzheimer’s Disease Curriculum Module VII: Disease Diagnosis.
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
How Alzheimer’s Disease Differs from Frontal Temporal Lobe Dementia (Pick’s Disease) Josepha A. Cheong, MD University of Florida Departments of Psychiatry.
Fractionation of Memory in Medial Temporal Lobe Amnesia
Recognition of Dementia Syed Zaman Consultant Physician Geriatric Medicine Palmerston North Hospital.
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.
New Learning and Remote Memory in Atypical Alzheimer’s Disease Yvonne Rogalski EXP 4504 December 3 rd, 2007 Thompson, Beswick, Foster, & Snowden (2003)
بسم الله الرحمن الرحیم. Dementia Dementia is a condition characterised by a progressive decline of mental abilities accompanied by changes in personality.
Clear organic causes, where primary symptom is a significant deficit in cognitive ability changes in the person’s personality and behavior (due to the.
Introduction Multiple Sclerosis (MS) is a chronic inflammatory disease characterized by the demyelization of axons within the central nervous system (CNS).
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
MEMORY ASSESSMENT in the LAB vs. the CLINIC
THE COGNITIVE DISORDERS Brian E. Wood, D.O. Associate Professor and Chair Department of Neuropsychiatry and Behavioral Sciences Edward Via Virginia College.
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
Delusions, behavioural symptoms, quality of life and caregiver effects in AD Delusions, behavioural symptoms, quality of life and caregiver effects in.
EXECUTIVE DYSFUNCTION AS A RISK MARKER FOR SUBSTANCE ABUSE: THE ROLE OF IMPULSIVE PERSONALITY TRAITS Sara L. Dolan 1, Antoine Bechara 2, Peter E. Nathan.
Detecting Individual Differences in Changes in Memory Functioning Dr. Len Lecci Professor of Psychology University of North Carolina Wilmington Director.
CU-1 Summary of Neuropathological and Clinical Features of PDD Clive Ballard, MD Professor of Age Related Diseases Institute of Psychiatry King’s College.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
How to diagnose dementia? Dr. Sridhar Vaitheswaran 25 th October 2012.
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
INTRODUCTION RESULTS METHODS CONCLUSIONS REFERENCES ACKNOWLEDGMENTS CONICET, CONICYT/FONDECYT.
Process Approach to Detecting Early Cognitive Impairment Rhoda Au, Ph.D., Friday Harbor 9/14/15 MBA.
1. Alzheimer Hellas 2. 3rd Department of Neurology, Medical School, Aristotle University of Thessaloniki, Greece 1. Alzheimer Hellas 2. 3rd Department.
CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.
Understanding Mild Cognitive Impairment. Objectives Understand the concept of MCI Identify risk factors for progression to dementia Review clinical trial.
 a type of dementia that causes problems with memory, thinking and behavior. Symptoms usually develop slowly and get worse over time, becoming severe.
Clinical, cognitive and genetic predictors of conversion from amnestic mild cognitive impairment to Alzheimer’s disease in Chinese older adults (Chu LW,
Cognitive Disorders Chapter 13 Nature of Cognitive Disorders: An Overview Perspectives on Cognitive Disorders Cognitive processes such as learning, memory,
Background. Vascular Cognitive Impairment Vascular Cognitive Impairment (VCI) includes the cognitive and behavioural disorders associated with cerebrovascular.
Identifying and Tracking Changes in Cognition Related to NPH Sheldon Herring, Ph.D. Clinical Director Outpatient Brain Injury and Young Stroke Program.
Additional Assessments. Clinicians are encouraged to communicate with the interprofessional team about other resources and next steps in terms of additional.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Alzheimer’s Disease Stephanie Aparicio May 4, 2011 Period 5.
Mild Cognitive Impairment, Activity Participation, Functional Difficulty, and Adaptations in Functionally Vulnerable Elderly People: A Closer Look Laraine.
1 Alzheimer’s Disease: Delirium and Dementia For use in conjunction with: The Eastern North Carolina Chapter of the Alzheimer’s Association. (2003). Module.
Types of Dementia Dr Bernie Coope Associate Medical Director/Honorary Senior Lecturer, Worcester University Association for Dementia Studies.
Memory and Aging Educational Presentation Presented by Tessa Lundquist, M.S. University of Massachusetts Amherst.
Frontotemporal Lobar Degeneration:
DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.
All Hands Meeting 2004 Ontologies for Data Mediation Christine Fennema-Notestine, Ph.D.
The Malfunctioning Mind: Degenerative Diseases of the Brain
Anne Moore Specialist in Special Care NHS Lanarkshire PDS
The Malfunctioning Mind: Degenerative Diseases of the Brain
Dementia Jaqueline Raetz, M.D..
Dementia Jaqueline Raetz, M.D..
University of South Alabama Neurobehavioural Associates
The need for the assessment of hearing loss as part of the dementia diagnosis Jenna Littlejohn Department of Neuroscience.
PPMI in the Medical Literature
Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI
Presentation transcript:

MCI in Lewy Body Disorders: Definition, Frequency, Progression and Differentiation from Other MCI Alexander I. Tröster, Ph.D. Department of Neurology University of North Carolina, Chapel Hill

Overview Nomenclature of Lewy body disorders Factors leading to consideration of “MCI” as an entity in Parkinson’s disease (PD) Potential benefits of identifying MCI in PD Frequency and subtypes of MCI in PD Conversion of MCI to PDD and DLB Dementia and the neuropsychological characteristics of the PDD prodrome Comparisons of neuropsychological characteristics of early PDD/DLB and Alzheimer’s disease Challenges facing the concept of MCI in Lewy body disorders Tröster 2009

Nomenclature of Lewy Body Disorders DLB/PDD Work Group (Lippa et al Parkinson’s disease (PD) Parkinson’s disease with dementia (PDD) Dementia with Lewy bodies (DLB) Lewy body dementias Distinction in temporal sequence of onset of motor symptoms and dementia in PDD and DLB retained in recent criteria (12 Month Rule) Tröster 2009

Cognitive Impairment in PD Cognitive changes in PD without dementia recognized for decades Cognitive changes near time of diagnosis recognized only recently (Foltynie et al. 2004, Muslimovic et al., 2005) First to refer to MCI in PD was review by Fernandez et al. 2005 Tröster 2009

Possible Factors Prompting Consideration of MCI in PD Acknowledgement of MCI heterogeneity and subtypes (Petersen 2004) Recognition of a) heterogeneous, and b) very early cognitive decrements in PD (Muslimovic et al. 2005) Neuropathologic staging of PD compatible with pre-diagnostic non-motor symptoms (Braak et al.2003) Tröster 2009

Possible Advantages of MCI Diagnosis in PD Early detection and treatment of cognitive decline, and consequent enhancement of functioning Evaluation of DLB/PDD distinction Greater precision in identifying course of cognitive decline, risk factors for these declines, and underlying mechanisms Tröster 2009

Evaluation and MCI Subtypes Tröster 2009

Montreal Cognitive Assessment (MOCA) Nasreddine et al. 2005 Tröster 2009

MCI Subtypes and Frequency in Parkinson’s Disease

Cognitive Impairment in Newly Diagnosed PD Muslimovic et al. 2005 24% (27) 3+ tests impaired; 38% 2+ tests impaired Tröster 2009

Tröster 2009

Tröster 2009

Tröster 2009

Progression of MCI to Parkinson’s Disease with Dementia (PDD)

Tröster 2009

MCI Progression to Dementia in PD Foltynie et al. (2004) did not define MCI but found 36% of newly diagnosed PD had cognitive impairment per one or more of MMSE and CANTAB Tower and Pattern Recognition Follow-up 3-5 years later (Williams-Gray et al. 2007) found the cognitive groupings were not informative of subsequent dementia, but dementia was associated with deficits on cognitive tests of “posterior” cortical functions (semantic fluency, pattern recognition, pentagon copying). Tröster 2009

Dementia and the Neuropsychological Characteristics of the PDD Prodrome

A Transition in Grouping PD Patients by Cognitive Impairment Tröster 2009

Neuropsychological Predictors of PDD Studies with Limited Assessment Instruments Piccirilli et al. (1989): 6/8 with (but only 1/22 without) “frontal dysfunction” per Luria tasks at baseline developed dementia at 4-year follow-up Biggins et al. (1992): Baseline WAIS Verbal & MMSE (but not WMS or WAIS Picture Completion) lower in 10 patients (of 82) developing dementia (54 months) than in 41 patients not developing dementia over 36 months Tröster 2009

Jacobs et al. (1995): Mahieux et al. (1998): Neuropsychological Predictors of PDD Studies with Multiple Assessment Instruments Jacobs et al. (1995): 23 of 111 (122) developed dementia at least 1 year follow-up predictors: lexical and semantic verbal fluency (without covariates, also immediate recall) Mahieux et al. (1998): 19 of 81 (89) developed dementia 3.5 year follow-up predictors: WAIS-R Picture Completion, Stroop interference, and lexical verbal fluency Tröster 2009

Neuropsychological Predictors of PDD Studies with Multiple Assessment Instruments Woods & Tröster (2003) 20 developed dementia after 1 year, 18 studied and compared to 18 PD not developing dementia PDD had poorer baseline performance in: Memory (CVLT Immediate recall & recognition) Executive function (WCST Perseverative Errors) Working memory (Digits backwards) Each of the 4 scores had good sensitivity in predicting PDD, but ≥ 2 of 4 scores impaired per ROC curve had 0.75 overall predictive power Tröster 2009

Progression of MCI to Dementia with Lewy Bodies (DLB)

Progression from MCI to DLB No MCI studies with DLB focus; two MCI studies incidentally/secondarily mention DLB Jicha et al. (2006) 34 amnestic-MCI developing dementia came to autopsy 1 had final clinical diagnosis of DLB 3 had neuropathologic diagnosis of Lewy body disease Fischer et al. (2007) 141 MCI and 440 normal followed 30 mos. Possible DLB in 10 patients with AD Baseline: 4 normal, 4 non-amnestic MCI, 2 amnestic MCI Tröster 2009

Neuropsychological Differentiation of LBD MCI and Other MCI

Retrospective Comparison of MCI-AD and MCI-DLB Jicha et al. 2009 Neuropathological database search 15 neuropathologically confirmed DLB (without significant comorbidity); 9 with predementia cognitive decline data 12 of 16 neuropathologically confirmed AD with predementia cognitive decline data MCI required memory complaint and impairment with intact functioning MCI-DLB: worse phonemic fluency MCI-AD: worse immediate paragraph recall Trends MCI-DLB slower on Trailmaking Part A MCI-AD worse on BNT, delayed wordlist recall Tröster 2009

Neuropsychological Comparisons of DLB, PDD and AD & Inferences about MCI Characteristics Caution needed in assuming neuropsychological differences in early dementia parallel those in MCI Assumes rate of progression of different deficits is similar Assumes linear progression of deficits Tröster 2009

Neuropsychological Comparison of DLB/PDD vs. AD AD involves greater impairment of memory, especially verbal (e.g., Noe et al., 2004; Simard et al. 2002), probably related to greater temporal lobe pathology AD hallmarks: rapid rates of forgetting and intrusions DLB involves greater visuoperceptual and constructional deficits (e.g., Simard et al. 2003; Calderon et al. 2001), which may be linked to posterior cortical hypometabolism and vissal hallucinations Tröster 2009

Neuropsychological Comparison of DLB/PDD vs. AD DLB/PDD perform worse than AD on complex attention tasks (Stroop, Trailmaking) (Calderon et al. 2001) but not on simple tasks (e.g., digit span) (Salmon et al. 1996) DLB/PDD perform worse on executive function tasks (e.g., card sorting) than AD (Simard et al. 2000; Paolo et al. 1995). Executive dysfunction linked to basal forebrain cholinergic deficits Language data more equivocal: same naming and fluency deficits in AD and DLB, worse naming in AD, worse letter fluency in DLB Tröster 2009

Summary of MCI in LBD

Summary of MCI in LBD MCI is present in 19% to 53% of PD, with most reports in the 20%-30% range In PD, MCI single domain more common than multiple domain Executive/attention seems most common domain of MCI in PD Executive/attention, and to lesser extent, immediate recall impairments are associated with development of dementia Virtually nothing known about MCI in DLB LBD MCI is neuropsychological differentiable from MCI/early AD Tröster 2009

Challenges to MCI in LBD

Challenges to the Concept of MCI in LBD Problems of studying MCI especially in DLB – low yield of DLB in MCI up to now. Will subtyping help? Should we start with MCI with parkinsonism? Many clinicians and patients think of MCI as a disease (or early AD) vs. a syndrome, thus risking confusion and fear of AD in PD Should behavioral abnormalities be considered in MCI given the PDD criteria? Tröster 2009

Challenges to the Concept of MCI in LBD Definition of MCI: which tests, which scores? How will MCI diagnosis aid treatment in PD? Role of PD medications in producing and alleviating/masking MCI? Should we call it PDCI analogous to vascular CI? Is memory impairment primary or secondary – affects definition of single vs. multiple domain MCI? Are subtypes too gross for prognostic purposes? Tröster 2009